(daunorubicin and cytarabine) liposome
(daunorubicin and cytarabine) liposome is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including VYXEOS. Available dosage form: injection, powder, lyophilized, for suspension.
Drug Details
- Generic Name
- (daunorubicin and cytarabine) liposome
- Brand Names
- VYXEOS
- Application Number
- NDA209401
- Sponsor
- Jazz Pharmaceuticals, Inc.
- NDC Codes
- 1
- Dosage Forms
- INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
- Routes
- INTRAVENOUS
- Active Ingredients
- CYTARABINE, DAUNORUBICIN
Indications and Usage
1 INDICATIONS AND USAGE VYXEOS is indicated for the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. ( 1 )